Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 1, 2015, Pages 5-19

  Bodei, Lisa ^a   Kidd, Mark ^b   Paganelli, Giovanni ^c   Grana, Chiara M ^a   Drozdov, Ignat ^b   Cremonesi, Marta ^a   Lepensky, Christopher ^b   Kwekkeboom, Dik J ^d   Baum, Richard P ^e   Krenning, Eric P ^d   Modlin, Irvin M ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

Bone marrow toxicity; Decision tree analysis; Nephrotoxicity; NET; PRRT

Indexed keywords

CAPECITABINE; CISPLATIN; ETOPOSIDE; HEMOGLOBIN; LUTETIUM 177; OCTREOTATE LU 177; OCTREOTIDE; OCTREOTIDE Y 90; SAMARIUM 153; UNCLASSIFIED DRUG; YTTRIUM 90; LUTETIUM; RADIOPHARMACEUTICAL AGENT; RECEPTOR; YTTRIUM;

ACUTE LEUKEMIA; ADULT; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CLINICAL FEATURE; CLINICAL STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DOSIMETRY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ITALY; LEUKOCYTE COUNT; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; RADIOTHERAPY; RANDOM FOREST; RECURSIVE PARTITIONING AND RERGRESSION TREE; RISK FACTOR; STATISTICAL MODEL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUROENDOCRINE TUMORS; RADIATION DOSE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LUTETIUM; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; YTTRIUM RADIOISOTOPES;

EID: 84912022479     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2893-5     Document Type: Article

References (31)

1. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62s–6s.
2. Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, et al. Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest. 2009;32:360–9.
3. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–35. doi:10.1007/s00259-011-1902-1.
4. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–23. doi:10.1200/jco.2010.33.7873.
5. Bushnell Jr DL, O’Dorisio TM, O’Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010;28:1652–9. doi:10.1200/jco.2009.22.8585.
6. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–62. doi:10.1200/jco.2005.08.066.
7. Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Nucl Med. 2011;52:1361–8. doi:10.2967/jnumed.111.087932.
8. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30. doi:10.1200/jco.2007.15.2553.
9. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53–73. doi:10.1677/erc-09-0078.
10. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8–e21. doi:10.1016/s1470-2045(13)70362-0.
11. Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, et al. Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging. 2007;34:772–86. doi:10.1007/s00259-006-0338-5.
12. Rolleman EJ, Kooij PP, de Herder WW, Valkema R, Krenning EP, de Jong M. Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging. 2007;34:1854–60.
13. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–56. doi:10.1007/s00259-008-0778-1.
14. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46 Suppl 1:83s–91s.
15. Churpek JE, Larson RA. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2013;26:309–17. doi:10.1016/j.beha.2013.09.001.
16. Dottorini ME, Salvatori M. Is radioiodine treatment for thyroid cancer a risk factor for second primary malignancies? Clin Transl Imaging. 2013;1:205–16. doi:10.1007/s40336-013-0022-2.
17. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med. 2010;51:1049–58. doi:10.2967/jnumed.110.075101.
18. Therneau T, Atkinson B, Ripley B. rpart: Recursive partitioning and regression times. 2014. http://cran.r-project.org/package=rpart/index.html.
19. Cremonesi M, Ferrari M, Di Dia A, Botta F, De Cicco C, Bodei L, et al. Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging. 2011;55:155–67.
20. Paganelli G, Sansovini M, Ambrosetti A, Severi S, Monti M, Scarpi E, et al. 177Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging. 2014. doi:10.1007/s00259-014-2735-5.
21. Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552–4. doi:10.1007/s002590100599.
22. Sabolic I, Asif AR, Budach WE, Wanke C, Bahn A, Burckhardt G. Gender differences in kidney function. Pflugers Arch. 2007;455:397–429. doi:10.1007/s00424-007-0308-1.
23. Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D’Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging. 2011;55:205–21.
24. Lane BR, Poggio ED, Herts BR, Novick AC, Campbell SC. Renal function assessment in the era of chronic kidney disease: renewed emphasis on renal function centered patient care. J Urol. 2009;182:435–43. doi:10.1016/j.juro.2009.04.004. discussion 43–4.
25. Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505–10. doi:10.1007/s00259-013-2601-x.
26. Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010;54:37–51.
27. Walrand S, Barone R, Pauwels S, Jamar F. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging. 2011;38:1270–80. doi:10.1007/s00259-011-1744-x.
28. Schroeder T, Kuendgen A, Kayser S, Kroger N, Braulke F, Platzbecker U, et al. Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica. 2012;97:206–12. doi:10.3324/haematol.2011.049114.
29. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35:418–29. doi:10.1053/j.seminoncol.2008.04.012.
30. Boehrer S, Ades L, Tajeddine N, Hofmann WK, Kriener S, Bug G, et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene. 2009;28:2205–18. doi:10.1038/onc.2009.69.
31. Kayser S, Dohner K, Krauter J, Kohne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117:2137–45. doi:10.1182/blood-2010-08-301713.